Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 11/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18860300 | 0.84 | PTPN1 (0.59) | — | |
| SCHEMBL11014128 | 0.79 | MAPT (0.58) | SMN1; SMN2GAAMAPK1LMNAHTT | |
| SCHEMBL13100303 | 0.78 | SMN1; SMN2 (0.59) | MLYCDNR1H3SMN1; SMN2RORCNR1H2 | |
| SCHEMBL4431611 | 0.78 | HSD17B3 (0.55) | MLYCDNR1H3SMN1; SMN2RORCNR1H2 | |
| SCHEMBL4877556 | 0.77 | MLYCD (0.58) | MLYCDNR1H3SMN1; SMN2RORCNR1H2 | |
| SCHEMBL3099164 | 0.76 | MLYCD (1.00) | MLYCDNR1H3SMN1; SMN2GAAMAPK1 | |
| SCHEMBL4420349 | 0.75 | HTR7 (0.60) | MLYCDNR1H3RORCNR1H2 | |
| SCHEMBL5169313 | 0.74 | PTPN1 (0.55) | SMN1; SMN2 | |
| SCHEMBL17148448 | 0.74 | KMT2A (0.52) | SMN1; SMN2GAAMAPK1LMNANPSR1 | |
| SCHEMBL21654210 | 0.73 | MMP2 (0.50) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-20 | — | — | US | claimed |
| US-7279477-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-09 | — | — | US | claimed |
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ACACA, ME1 | MLYCD 1/4885NR1H3 1471/4885SMN1; SMN2 2729/4885 |
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | MLYCD 1/4885NR1H3 1405/4885SMN1; SMN2 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.